Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 3/20 | 1.00 |
| ▸ | SERPINA6 | P08185 | 6/20 | 0.66 |
| ▸ | SHBG | P04278 | 7/20 | 0.65 |
| ▸ | LMNA | P02545 | 6/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | BLM | P54132 | 4/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | PGR | P06401 | 2/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.60 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.56 |
| ▸ | TSHR | P16473 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29409283 | 1.00 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL29500568 | 1.00 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL4539514 | 1.00 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL7993136 | 1.00 | CYP17A1 (1.00) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| Algestone Acetonide SCHEMBL42582 | 0.92 | CYP17A1 (0.85) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL151266 | 0.87 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| Algestone Acetophenide SCHEMBL1649218 | 0.87 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| Algestone Acetophenide SCHEMBL3039564 | 0.87 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| Algestone Acetophenide SCHEMBL282250 | 0.87 | CYP17A1 (0.76) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 | |
| SCHEMBL27759498 | 0.85 | CYP17A1 (0.73) | CYP17A1SERPINA6SHBGLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117030904-B | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-12-19 | — | — | CN | claimed |
| CN-117164875-A | Preparation method of tubular metal copper phthalocyanine polymer and cyclic carbonate | 浙江理工大学 | 2023-12-05 | — | — | CN | claimed |
| CN-117030904-A | Method for measuring 144 steroid hormones in environmental sample by liquid chromatography-mass spectrometry | 北京林业大学 | 2023-11-10 | — | — | CN | claimed |
| CN-111020841-B | Deodorant garment materials | 迈科凯普(杭州)生物科技有限公司 | 2021-07-13 | — | — | CN | claimed |
| CN-111020841-A | Deodorant garment materials | 顾正明 | 2020-04-17 | — | — | CN | claimed |
| CN-108254365-B | A kind of the magnetic immunochemiluminescence detection kit and its application of progesterone | 北京勤邦生物技术有限公司 | 2019-11-05 | — | — | CN | claimed |
| CN-117164875-A | Preparation method of tubular metal copper phthalocyanine polymer and cyclic carbonate | 浙江理工大学 | 2023-12-05 | — | — | CN | disclosed |
| US-20230296574-A1 | ANALYSIS METHOD AND ANALYSIS SYSTEM FOR BILE ACIDS, STEROLS, AND HORMONES | KAZUSA DNA RESEARCH INSTITUTE (JP) | 2023-09-21 | — | — | US | disclosed |
| EP-4209782-A1 | ANALYSIS METHOD AND ANALYSIS SYSTEM FOR BILE ACIDS, STEROLS, AND HORMONES | Aderans Company Limited (JP) | 2023-07-12 | — | — | EP | disclosed |
| CN-116075720-A | Method and system for analyzing bile acids, sterols and hormones | 爱德兰丝株式会社 | 2023-05-05 | — | — | CN | disclosed |
| US-20220175819-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | FOUNT BIO, INC. | 2022-06-09 | — | — | US | disclosed |
| EP-3336098-B1 | SKIN PERMEABLE PEPTIDE AND METHOD FOR USING SAME | IUCF HYU (KR) | 2021-08-11 | — | — | EP | disclosed |
| CN-111020841-B | Deodorant garment materials | 迈科凯普(杭州)生物科技有限公司 | 2021-07-13 | — | — | CN | disclosed |
| US-20120165526-A1 | Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2012-06-28 | — | — | US | disclosed |
| US-20120128756-A1 | Skin Permeating And Cell Entering (SPACE) Peptides and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-05-24 | — | — | US | disclosed |
| WO-2012064429-A2 | SKIN PERMEATING AND CELL ENTERING (SPACE) PEPTIDES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-18 | — | — | WO | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-4397947-A | NOCARDIA | G. D. SEARLE & CO. (US) | 1983-08-09 | — | — | US | disclosed |
| US-4322349-A | Process for preparing 6-methylene steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175819-A1 | DELIVERY AND RETENTION OF ACTIVE AGENTS WITHIN THE SKIN | MMP8, MMP7, MMP1 | CYP17A1 3096/4885SERPINA6 221/4885SHBG 2570/4885 |
| US-20120165526-A1 | Useful Pharmaceutical Salts of 7- [(3R, 4R) - 3 - Hydroxy -4 - Hydroxymethyl - Pyrrolidin -1- Ylmethyl] -3, 5-Dihydro-Pyrrolo [3, 2-D] Pyrimidin -4-One | HPD, PGD, DPYD | CYP17A1 2511/4885SERPINA6 2927/4885SHBG 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.